Biotech News
Related news
MGTXMeiraGTx2026-08-13 12:00 EST
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
MGTXMeiraGTx2026-08-06 20:30 EST
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ARWRArrowhead Pharmaceuticals2026-08-24 11:30 EST
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
TSHATaysha Gene Therapies2026-08-03 12:00 EST
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
OCGNOcugen2026-07-29 11:01 EST
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration
CRBUCaribou2026-06-29 12:00 EST
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
BCRXBioCryst Pharmaceuticals2026-06-12 11:00 EST
BioCryst Presents New Clinical Data and Real-World Evidence Demonstrating Impact of HAE Portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
MXCTMaxCyte2026-07-21 12:05 EST
MaxCyte® Announces Multi-Platform Technology License Partnership with Genentech® to Advance Cell Therapy Development
OCGNOcugen2026-07-13 11:02 EST
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
SANASana Biotechnology2026-07-01 13:00 EST
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
MeiraGTx
Genetic Medicines Company MeiraGTx develops and manufactures gene therapies for inherited retinal disease, salivary-gland disorders, and other conditions. Its vertically integrated model spans vector design, clinical development, and commercial manufacturing. Bota-Vec Botaretigene sparoparvovec is an AAV gene therapy for X-linked...
Recent company news
MGTXMeiraGTx2026-08-13 12:00 EST
MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
MGTXMeiraGTx2026-08-06 20:30 EST
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MGTXMeiraGTx2026-07-07 11:30 EST
MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)
MGTXMeiraGTx2026-05-14 20:30 EST
MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
MGTXMeiraGTx2026-05-14 12:00 EST
MeiraGTx Reports First Quarter 2026 Financial and Operational Results
Stock data
- Close
- 14.34 USD
- Market cap
- 855.71M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States